Correction: Peglated-H1/pHGFK1 nanoparticles enhance anti-tumor effects of sorafenib by inhibition of drug-induced autophagy and stemness in renal cell carcinoma

Correction : J Exp Clin Cancer Res 38, 362 (2019)

https://doi.org/10.1186/s13046-019-1348-z

Following publication of the original article [1], the authors identified an error in Fig. 9, specifically:

• Fig. 9a - the representative IHC figure of LC3B in PH1/HGFK1 + sorefenib group was repetitive to PH1/pVehicle group

The correct figure is given below.

Fig. 9

Effect of sorafenib and HGFK1 on the expression of LC3B, phosphorylated NF-κB, CD133, Nanog, and Oct4 in vivo. Tumor tissues from sorafenib and/or HGFK1 treated tumor-bearing mice were collected and stained with IHC. The expression of LC3B and phosphorylated NF-κB (a), as well as CD133, Nanog, and Oct4 (b) on tumor tissues was analyzed and quantified with IOD. All data shown represent the mean ± SD from three to five independent sections. Significant differences are denoted by ** for p < 0.01, and *** for p < 0.001